Tehran Heart Center
11
0
0
6
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 25/100
0.0%
0 terminated/withdrawn out of 11 trials
100.0%
+13.5% vs industry average
55%
6 trials in Phase 3/4
17%
1 of 6 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (11)
Empagliflozin to Prevent Post-Operative Atrial Fibrillation
Role: collaborator
Rivaroxaban vErsus Warfarin for Antithrombotic TheRapy in Patients With LeFt Ventricular Thrombus After Acute STEMI
Role: collaborator
Compression Stockings for Treating Vasovagal Syncope Trial
Role: lead
Intermediate-dose vs Standard Prophylactic Anticoagulation and Statin vs Placebo in ICU Patients With COVID-19
Role: collaborator
Midodrine and Fludrocortisone for Vasovagal Syncope
Role: lead
Evaluation of Long-term Coronary Stenting Outcomes in Diabetic Patients With or Without Optimal Glycemic Control
Role: lead
N-Acetyl Cystein and Contrast Nephropathy
Role: collaborator
Nephrogenic Systemic Fibrosis With Gadollinum
Role: collaborator
Prevalence of Renal Artery Stenosis in Patients Referred for Cardiac Catheterization
Role: collaborator
Preventing Contrast Nephropathy With Sodium Bicarbonate in Patients With Pulmonary Edema,Heart Failure,Uncontrolled HTN
Role: collaborator
Effect of Sodium Bicarbonate Solution in Decreasing the Incidence of Contrast Induced Nephropathy (CIN)
Role: collaborator
All 11 trials loaded